Bevacizumab biosimilar (Biocnd)

贝伐珠单抗生物类似药（Biocnd）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBevacizumab biosimilar (Biocnd)

Drug Alias Name贝伐赛珠单抗生物仿制药（Biocnd）贝伐珠单抗生物类似药（Biocnd）贝伐人源化单抗生物仿制药（Biocnd）贝伐单抗生物仿制药（Biocnd）BCD-500

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiocnd

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBiocnd

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeL01XC07